Wolf SM, Lawrenz FP, Nelson CA, et al. Managing incidental findings in human subjects research: analysis and recommendations. J Law Med Ethics 2008;36:219–248, 1.
Wright CF, Middleton A, Burton H, et al. Policy challenges of clinical genome sequencing. BMJ 2013;347:f6845.
Green RC, Berg JS, Grody WW, et al.; American College of Medical Genetics and Genomics. ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing. Genet Med 2013;15:565–574.
Townsend A, Adam S, Birch PH, Friedman JM. Paternalism and the ACMG recommendations on genomic incidental findings: patients seen but not heard. Genet Med 2013;15:751–752.
Vayena E, Tasioulas J. Genetic incidental findings: autonomy regained? Genet Med 2013;15:868–870.
Holtzman NA. ACMG recommendations on incidental findings are flawed scientifically and ethically. Genet Med 2013;15:750–751.
Rosenblatt DS. Who’s on first in exome and whole genome sequencing? Is it the patient or the incidental findings? Mol Genet Metab 2013;110:1–2.
Allyse M, Michie M. Not-so-incidental findings: the ACMG recommendations on the reporting of incidental findings in clinical whole genome and whole exome sequencing. Trends Biotechnol 2013;31:439–441.
Evans BJ. Minimizing liability risks under the ACMG recommendations for reporting incidental findings in clinical exome and genome sequencing. Genet Med 2013;15:915–920.
American College of Medical Genetics and Genomics. ACMG Updates Recommendation on “Opt Out” for Genome Sequencing Return of Results. https://www.acmg.net/docs/Release_ACMGUpdatesRecommendations_final.pdf. Accessed 15 April 2014.
Haverfield AD, Fuller A, Smaoui N, et al. Evaluation of ACMG Recommended Incidental Findings in Clinical Whole Exome Sequencing. Abstract presented at ASHG. http://www.ashg.org/2013meeting/abstracts/fulltext/f130122357.htm. Accessed 7 September 2014.
Ademi Z, Watts GF, Pang J, et al. Cascade screening based on genetic testing is cost-effective: evidence for the implementation of models of care for familial hypercholesterolemia. J Clin Lipidol 2014;8:390–400.
Ingles J, McGaughran J, Scuffham PA, Atherton J, Semsarian C. A cost-effectiveness model of genetic testing for the evaluation of families with hypertrophic cardiomyopathy. Heart 2012;98:625–630.
Reed SD, Dinan MA, Schulman KA, Lyman GH. Cost-effectiveness of the 21-gene recurrence score assay in the context of multifactorial decision making to guide chemotherapy for early-stage breast cancer. Genet Med 2013;15:203–211.
Elkin EB, Marshall DA, Kulin NA, et al. Economic evaluation of targeted cancer interventions: critical review and recommendations. Genet Med 2011;13:853–860.
Wordsworth S, Leal J, Blair E, et al. DNA testing for hypertrophic cardiomyopathy: a cost-effectiveness model. Eur Heart J 2010;31:926–935.
Mvundura M, Grosse SD, Hampel H, Palomaki GE. The cost-effectiveness of genetic testing strategies for Lynch syndrome among newly diagnosed patients with colorectal cancer. Genet Med 2010;12:93–104.
Pagon RA, Adam MP, Bird TD, et al. (eds). GeneReviews. University of Washington, Seattle: Seattle, WA, 1993–2014. http://www.ncbi.nlm.nih.gov/books/NBK1116/. Accessed 18 March 2014.
Marks D, Wonderling D, Thorogood M, Lambert H, Humphries SE, Neil HA. Screening for hypercholesterolaemia versus case finding for familial hypercholesterolaemia: a systematic review and cost-effectiveness analysis. Health Technol Assess 2000;4:1–123.
Marks D, Wonderling D, Thorogood M, Lambert H, Humphries SE, Neil HA. Cost effectiveness analysis of different approaches of screening for familial hypercholesterolaemia. BMJ 2002;324:1303.
Nherera L, Calvert NW, Demott K, et al. Cost-effectiveness analysis of the use of a high-intensity statin compared to a low-intensity statin in the management of patients with familial hypercholesterolaemia. Curr Med Res Opin 2010;26:529–536.
Centers for Disease Control and Prevention. Prevalence of Cholesterol Screening and High Blood Cholesterol Among Adults—United States, 2005, 2007, and 2009. Morbidity and Mortality Weekly Report (MMWR) 2012;61(35):697–702. http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6135a2.htm. Accessed 7 September 2014.
Perez MV, Kumarasamy NA, Owens DK, Wang PJ, Hlatky MA. Cost-effectiveness of genetic testing in family members of patients with long-QT syndrome. Circ Cardiovasc Qual Outcomes 2011;4:76–84.
Holland ML, Huston A, Noyes K. Cost-effectiveness of testing for breast cancer susceptibility genes. Value Health 2009;12:207–216.
National Institute for Health and Clinical Excellence. Full cost effectiveness evidence review & reports, 2013. Familial breast cancer: classification and care of women at risk of familial breast cancer and management of breast cancer and related risks in people with a family history of breast cancer. Developed for NICE by the National Collaborating Centre for Cancer. http://www.nice.org.uk/guidance/cg164/resources/cg164-familial-breast-cancer-cost-effectiveness-evidence-review2. Accessed 3 May 2014.
Ladabaum U, Wang G, Terdiman J, et al. Strategies to identify the Lynch syndrome among patients with colorectal cancer: a cost-effectiveness analysis. Ann Intern Med 2011;155:69–79.
Dinh TA, Rosner BI, Atwood JC, et al. Health benefits and cost-effectiveness of primary genetic screening for Lynch syndrome in the general population. Cancer Prev Res (Phila) 2011;4:9–22.
Wang G, Kuppermann M, Kim B, Phillips KA, Ladabaum U. Influence of patient preferences on the cost-effectiveness of screening for lynch syndrome. J Oncol Pract 2012;8(suppl 3):e24s–e30s.
Dorschner MO, Amendola LM, Turner EH, et al.; National Heart, Lung, and Blood Institute Grand Opportunity Exome Sequencing Project. Actionable, pathogenic incidental findings in 1,000 participants’ exomes. Am J Hum Genet 2013;93:631–640.
Garrison LP Jr, Mansley EC, Abbott TA 3rd, Bresnahan BW, Hay JW, Smeeding J. Good research practices for measuring drug costs in cost-effectiveness analyses: a societal perspective: the ISPOR Drug Cost Task Force report–Part II. Value Health 2010;13:8–13.
Ding LE, Burnett L, Chesher D. The impact of reporting incidental findings from exome and whole-genome sequencing: predicted frequencies based on modeling. Genet Med 2014; e-pub ahead of print 31 July 2014.
Begg CB, Haile RW, Borg A, et al. Variation of breast cancer risk among BRCA1/2 carriers. JAMA 2008;299:194–201.
Burke W, Matheny Antommaria AH, Bennett R, et al. Recommendations for returning genomic incidental findings? We need to talk! Genet Med 2013;15:854–859.
Berg JS, Amendola LM, Eng C, et al.; Members of the CSER Actionability and Return of Results Working Group. Processes and preliminary outputs for identification of actionable genes as incidental findings in genomic sequence data in the Clinical Sequencing Exploratory Research Consortium. Genet Med 2013;15:860–867.
Kuppermann M, Wang G, Wong S, et al. Preferences for outcomes associated with decisions to undergo or forgo genetic testing for Lynch syndrome. Cancer 2013;119:215–225.
Foster MW, Mulvihill JJ, Sharp RR. Evaluating the utility of personal genomic information. Genet Med 2009;11:570–574.
Bennette CS, Trinidad SB, Fullerton SM, et al. Return of incidental findings in genomic medicine: measuring what patients value–development of an instrument to measure preferences for information from next-generation testing (IMPRINT). Genet Med 2013;15:873–881.
Centers for Disease Control and Prevention. FastStats, Inpatient Surgery. http://www.cdc.gov/nchs/fastats/insurg.htm. Accessed 18 March 2014.
Malignant Hyperthermia Association of the United States. FAQs: Stocking an MH Cart. http://www.mhaus.org/faqs/stocking-an-mhcart. Accessed 18 March 2014.
Dantrium IV. Direct order form from JHP Pharmaceuticals. http://www.dantrium.com/dantriumiv/dantriumiv_eform.pdf. Accessed 14 April 2014.
Malignant Hyperthermia Association of the United States. Anesthesia Workstation Preparation. http://www.mhaus.org/healthcare-professionals/mhaus-recommendations/anesthesia-workstation-preparation. Accessed 18 March 2014.
Dynasthetics Vapor-Clean. Online catalogue. http://www.dynasthetics.com/store/vapor-clean.html. Accessed 18 March 2014.
Hirshey Dirksen SJ, Larach MG, Rosenberg H, Brandom BW, Parness J, Lang RS, et al. Special article: Future directions in malignant hyperthermia research and patient care. Anesth Analg 2011;113:1108–1119.
Maron BJ, Olivotto I, Spirito P, Casey SA, Bellone P, Gohman TE, et al. Epidemiology of hypertrophic cardiomyopathy-related death: revisited in a large non-referral-based patient population. Circulation 2000;102:858–864.
Marcus GM, Glidden DV, Polonsky B, Zareba W, Smith LM, Cannom DS, et al. Efficacy of antiarrhythmic drugs in arrhythmogenic right ventricular cardiomyopathy: a report from the North American ARVC Registry. J Am Coll Cardiol 2009;54:609–615.
Groeneveld PW, Matta MA, Suh JJ, Heidenreich PA, Shea JA. Costs and quality-of-life effects of implantable cardioverter-defibrillators. Am J Cardiol 2006;98:1409–1415.
Healthcare Bluebook. CAREOperative, 2014. http://www.healthcarebluebook.com/page_Default.aspx. Accessed 18 March 2014.
Guzauskas GF, Boudreau DM, Villa KF, Levine SR, Veenstra DL. The cost-effectiveness of primary stroke centers for acute stroke care. Stroke 2012;43:1617–1623.
Unroe KT, Greiner MA, Hernandez AF, Whellan DJ, Kaul P, Schulman KA, et al. Resource use in the last 6 months of life among medicare beneficiaries with heart failure, 2000-2007. Arch Intern Med 2011;171:196–203.
Brandle M, Davidson MB, Schriger DL, Lorber B, Herman WH. Cost effectiveness of statin therapy for the primary prevention of major coronary events in individuals with type 2 diabetes. Diabetes Care 2003;26:1796–1801.
Nherera L, Calvert NW, Demott K, Humphries SE, Neil HA, Minhas R, et al. Cost-effectiveness analysis of the use of a high-intensity statin compared to a low-intensity statin in the management of patients with familial hypercholesterolaemia. Curr Med Res Opin 2010;26:529–536.